Your SlideShare is downloading. ×
ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, London, UK. May 2010
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

ACT Presentation at Rodman & Renshaw Annual Global Investment Conference, London, UK. May 2010

74
views

Published on

Corporate Presentation …

Corporate Presentation

5/16/2010

Published in: Technology, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
74
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Advanced Cell TechnologyCorporate PresentationMay 20101
  • 2. This presentation is intended to present a summary of ACT’s (“ACT”, or “AdvancedCell Technology Inc”, or “the Company”) salient business characteristics.The information herein contains “forward-looking statements” as defined under thefederal securities laws. Actual results could vary materially. Factors that could causeactual results to vary materially are described in our filings with the Securities andExchange Commission.You should pay particular attention to the “risk factors” contained in documents wefile from time to time with the Securities and Exchange Commission. The risksidentified therein, as well as others not identified by the Company, could cause theCompany’s actual results to differ materially from those expressed in any forward-looking statements.Cautionary Statement Concerning Forward-LookingStatements2
  • 3. State of the Company• Two years of cash available• Phase I/II trial fully funded• Anticipating cell lines will qualify forfederal funding• Actively pursuing development partnersoffshore to accelerate development ofprograms3
  • 4. ACT TherapeuticsACT Proprietary HumanTherapeutic ProgramsTreatment Clinical StageBlastomere ProgramDevelopment of embryonic stem cell lines withoutdestruction of embryoPre-ClinicalRetinal Pigment Epithelium(RPE) ProgramTreatment of Age-related Macular Degeneration(AMD) and Retinal Degenerative DiseasesClinical INDawaitingFDA approvalMyoblast ProgramTreatment of Heart Disease, Heart Attack andHeart FailurePhase IIHemangioblast programTreatment of Diseases and Disorders of theCirculatory and Vascular SystemsPre-Clinical4
  • 5. PendingMultiple next generation technologies complementary toexisting patents and claimsPendingMultiple use patents for heart diseaseStatusUse PatentsPendingCombinations of myoblasts and stem cellsPendingCombinations of myoblasts and muscle survival factorsPendingCatheter delivery of cellsAwardedMedia for preservation and transplant of muscle cellsAwardedStem cells capable of forming nerve or muscle cellsAwardedMuscle cellsStatusComposition of Matter PatentIntellectual Property ProtectionACT owns or licenses over 150 patents and patent applications related tostem cell and regenerative therapies5
  • 6. Institutional CollaboratorsAdvanced Cell’s Institutional Collaborators include:Casey Eye Institute Mayo ClinicMoran Eye Institute UCSFHarvard Johns HopkinsStanford Sloan KetteringUniversity of Florida University of IowaUniversity of Illinois U.C. BerkeleyColorado State University6
  • 7. Blastomere Program: Synthesizing Stem Cellswithout Harm to the Embryo•Company scientists successfully generate stemcell lines without destruction of embryo•Cell lines retain potential to form all cells in thehuman body•Potential to treat a range of human diseases•Technology has been reproduced and peer-reviewed on several occasions•National Institute of Health (NIH) proposingexpanded funding regulations to accommodateACT’s lines7
  • 8. First Proven Alternative hESC Method•Enables Derivation of New hESC Linesvia Pre-implantation Genetic Diagnosis(PGD) Method, Preserving DevelopmentPotential of the Embryo•7 hESC lines awaiting NIH approval forfunding•Technology is used to develop RPE cells forour clinical trials for Stargardt’s diseaseHemangioblastsDifferentiated fromBlastomere hESC Lines8
  • 9. RPE Program: Why RPE?• Pigmented epithelium cells are easy to identify• Small dosage vs. other therapies• The eye is an immune-privileged site, thus no riskof rejection at the injection site• Ease of administration– Doesn’t require a separate approval by the FDA (universal applicator)– Procedure is already used by eye surgeons; no new skill set requiredfor doctors• RPE cell therapy may positively impact over 200 retinal diseases9
  • 10. RPE Program Status2010 – 1st Quarter2010 – 1st QuarterComplete response addressing FDA concerns2010 – 2nd QuarterFDA approval2010 – 3rd Quarter10Received Orphan Drug StatusNIH proposed new definition of hESCs forfunding2009 – 4th Quarter Filed IND with FDA
  • 11. GMP-compliant Human RPE Cells Derived from Embryonic Stem CellLines Rescue Visual Function In a Rat Model for PhotoreceptorDegeneration“Our results show that a well-characterized GMP-compliant embryonic stem cell-derived RPEcells can survive after transplantation to the sub-retinal space of RCS rats, integrate into hostRPE layer without migration into the retina and continue to express at least some of themolecules characteristic of RPE. The cells are effective in rescuing photoreceptors fromdegeneration and result in significant rescue of visual function over sham-operated animals forthe long term.”CASEY EYEINSTITUTE11
  • 12. Myoblast Program HighlightsTarget Market for Myoblast ProgramSufferers of Heart Failure, Chronic HeartFailure and patients with scarred orischemic (dead) heart tissue caused byor related to heart attackProgram StatusClearance from FDA to Proceed withPhase II Clinical Trials in the U.S.Charlestown, MA GMP Facility12
  • 13. Myoblast Program: Clinical Trial SummaryPhase 1LVADPhase 1CABGPhase 1bCABGPhase 1bCatheterPatients 6 patients 12 patients 12 patients23 Patients(12 treated,11 control)IndicationLVAD Bridgeto Transplant+CABG +CABG Catheter InjectionDoseSingle Dose -300 MM CellsEscalating –10, 30, 100 and300 MM CellsSingle Dose -300 MM CellsEscalating -30, 100, 300 and600 MM CellsPrimaryEndpointSafety Safety Safety SafetyResultDemonstratedcell survival inhumansDoseescalation, Safeat all dosesSurvival of cells(cardiacimaging),improvedsymptoms andfunctionSafe at all doses,improvedsymptoms andfunction13
  • 14. Catheter Trial – Responder Analysis14NYHA Classification at 6 month vs Baseline for all PatientsImproved No Change WorsenedMyoblast 83% 17% 0%Control 0% 64% 36%
  • 15. Myoblast Program: Phase II Clinical Trial 80 total patients (1:1 treatment vs. control) Double-blind, placebo-controlled (sham procedure) Catheter delivery of cells: percutaneous targeted delivery Three-month, six-month, and 12-month follow-up Endpoints: Improvement in HF symptoms and VentricularVolumes Primary endpoint: Improvement in heart failure symptomsmeasured by “Kansas City Cardiomyopathy Questionnaire” Supporting endpoints: Ventricular volumes, Six minute walk test Interim data analysis at six-months by Independent Review Board15
  • 16. Hemangioblast Program: Partnership• Joint Venture with leading Korean stem celldeveloper CHA Biotech Co.• The J.V., ‘Stem Cell & RegenerativeMedicine International’, is focused on thedevelopment of human blood cells andrelated products16
  • 17. Hemangioblast Program: OverviewThe HG cell is the precursor to all cell types in thecirculatory and vascular systems17
  • 18. Hemangioblast Program: Synthesizing Blood Cells18
  • 19. The ACT Therapeutic TimelineTimetable for Therapeutic Program Milestones PeriodReceived Orphan indication from Department of Healthand Human ServicesQ1 2010Completion of end of life tumorgenicity & biodistributionstudies for RPEQ1 2010Receive FDA clearance to commence with Phase I ClinicalTrialsQ3 2010Treat 1st Patient in history with a hECS-based therapy Q4 20101st Quadrant Safety Data on Treated Patients2nd half2010File 2nd Phase I IND for another Retinal Disease2nd half2010Announce 2nd cellular-based IND in area other thanretinal programQ1 201119
  • 20. The Advanced Cell Technology TeamWorld Class Scientific Team lead bySeasoned Management Team:Dr. Robert Lanza, M.D. – Chief Scientific OfficerDr. Jonathan Dinsmore, PhD – Myoblast Project AdvisorMatthew Vincent, PhD – IP / Licensing Advisor20William Caldwell IV – Chief Executive OfficerEdmund Mickunas – Vice President of RegulatoryRoger Gay, PhD – Senior Director of ManufacturingRita Parker – Director of Operations
  • 21. Thank you for your timeFor more information, visit www.advancedcell.comAdvanced Cell Technology is traded on the OTC BB, symbol: ACTC